Special Issue

Neurodevelopmental Disabilities

Message from the Guest Editor

Neurodevelopmental disabilities is a long-standing and overarching term covering a range of developmental challenges related to irregular brain function including, but not limited to, attention deficit hyperactivity disorder (ADHD): autism spectrum disorder (ASD): communication; speech or language disorders; dyslexia and dyscalculia; fetal alcohol spectrum disorders (FASDs); global developmental delay (GDD); intellectual disabilities (IDs); neonatal abstinence syndrome (NAS); and neurogenic disorders and traumatic brain injury (TBI) in infants, children, and youth. The complexity of growing and aging with a neurodevelopmental disability is now being recognized, along with a lack of societal support which induces aging. Some neurodevelopmental disabilities are recognized to be genetically related, and neurodevelopmental disabilities are diagnosed more frequently in males versus females. New research knowledge about neurodevelopmental conditions will be presented in this Special Issue of Biomedicines.

Guest Editor

Dr. Charlotte Royeen

College of Health Sciences, Rush University, Chicago, IL 60612, USA

Deadline for manuscript submissions

closed (30 September 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/139467

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health. Boston. MA 02115. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).